Karachi, The Pakistan General Insurance Company Limited has reported significant share transactions executed by Ali Shahzad, a substantial shareholder of the company. On July 27, 2023, Ali Shahzad bought a total of 4,686,748 shares in two separate tran…
The post Substantial Shareholder Ali Shahzad Buys Significant Number of
Karachi, In a recent development, Engro Corporation Limited has cancelled 39,536,762 ordinary shares purchased during the buy-back process. The cancellation was carried out in accordance with Regulation I0(d) of the Listed Companies (Buy-Back of Shares…
The post Engro Corporation Limited Cancels 39.5 Million Shares Purchased During Buy-Back, Reducing
Karachi, Millat Tractors Limited has reported that its Non-Executive Director, Sikandar Mustafa Khan, executed a buy transaction in shares of the company. On August 1, 2023, Mr. Khan purchased 71 shares at a rate of 397.90 per share through CDC in the …
The post Non-Executive Director Sikandar
Karachi, Kohinoor Textile Mills Limited has successfully completed its buy-back of 201,500 ordinary shares at Rs. 53.00 per share, pursuant to the Special Resolution passed in the Extraordinary General Meeting held on March 03, 2023. The buy-back was c…
The post Kohinoor Textile Mills Limited Successfully Executes Buy-Back
Lahore, August 02, 2023 (PPI-OT): His Excellency Shahid Ahmed Khan, Advisor to President of the United States of America visited Pakistan China Joint Chamber of Commerce and Industry (PCJCCI) on Wednesday at PCJCCI Secretariat to discuss trilateral rel…
As part of the MILGEM project, the fourth warship, named PNS TARIQ, will be launched on Wednesday in Pakistan’s southern port city of Karachi.The MILGEM ships were built simultaneously in Türkiye and Pakistan for the Pakistani Navy by Türkiye’s Militar…
Pakistan and China are celebrating as the China-Pakistan Economic Corridor, the centerpiece of Beijing’s global Belt and Road initiative, completes 10 years. The investment project has grown to over $60 billion and provided Pakistan with crucial infras…
Study found obexelimab produced rapid, strong, and sustained clinical improvement, including complete clinical remission, in most patients with active IgG4-RD Results support the continued development of obexelimab for the treatment of IgG4-RD and potentially other B cell-mediated autoimmune conditions WALTHAM, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) — Zenas BioPharma, a